Evaluating Circulating Tumor Cells in Breast Cancer Follow-up

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on the use of liquid biopsy to detect and quantify circulating tumor cells (CTCs) in patients with breast cancer. Utilizing ScreenCell technology, it aims to monitor the evolution of CTCs during the follow-up phase of breast cancer treatment. By identifying and characterizing these cells, the study seeks to provide insights into the stage and molecular characteristics of the cancer. Participants include those with metastatic and non-metastatic breast cancer, as well as healthy volunteers for comparison.

Why it matters

Who can join: the full rules

INCLUSION CRITERIA

For all participants :

* Female with age greater than or equal to 18 years

For participants with metastatic breast cancer:

\- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion.

For participants with non-metastatic invasive breast cancer:

\- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment)

For healthy volunteers:

* Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion
* Participant with no history of cancer

EXCLUSION CRITERIA

For all participants:

* Male
* Age less than 18 years old
* Refusal to participate or withdrawal of consent
* Pregnant and/or breastfeeding women
* Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up.

For healthy volunteers:

* History of cancer
* Detection of CTC (positive profile) during screening

Where it's running

• CMC Ambroise Paré Hartmann
  Neuilly-sur-Seine, France Recruiting

Study contacts

• Study coordinator: Jessica GROULT, Ph.D
• Email: jgroult@screencell.com
• Phone: 0033669645318

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating anticancer drug therapies for gynecologic and breast cancers

  This study is testing different cancer drug treatments to see how well they work and how well patients with breast and gynecologic cancers can tolerate them.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06800612

• Regular exercise to help women with early-stage breast cancer on hormone therapy

  This study tests whether a guided, 16-week exercise program improves quality of life and fitness for women with early-stage breast cancer who are starting adjuvant hormone therapy.

  Recruiting Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares · San Sebastián de los Reyes, Madrid · NCT07893327

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Decision Support Tool for People with Advanced Breast Cancer

  This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.

  Recruiting at 3 sites Weill Medical College of Cornell University · Brooklyn, New York and 2 other locations · NCT07635147

• HER2-PET to Predict T-DXd Benefit in Advanced Breast Cancer

  This study tests whether HER2-PET imaging can help predict how well T-DXd will work for adults with advanced HER2-positive or HER2-low breast cancer receiving the drug.

  Recruiting Fudan University · Shanghai · NCT07586215

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.